• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Introduction to (6-Bromopyrimidin-4-yl)methanol: CAS No. 1805551-65-8

(6-Bromopyrimidin-4-yl)methanol, identified by the CAS number 1805551-65-8, is a chemical compound that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound belongs to the class of pyrimidine derivatives, which are known for their diverse biological activities and applications in drug discovery. The structure of (6-Bromopyrimidin-4-yl)methanol consists of a pyrimidine ring substituted with a bromine atom at position 6 and a hydroxymethyl group at position 4, making it a valuable molecule for further exploration in medicinal chemistry.

Recent studies have highlighted the potential of pyrimidine derivatives as promising candidates for the development of new therapeutic agents. For instance, research published in the Journal of Medicinal Chemistry has demonstrated that (6-Bromopyrimidin-4-yl)methanol exhibits significant inhibitory activity against certain enzymes involved in cancer progression. This finding underscores the importance of this compound in anticancer drug development.

The synthesis of (6-Bromopyrimidin-4-yl)methanol involves a multi-step process that typically begins with the preparation of the pyrimidine ring. One common approach is the Biginelli reaction, which allows for the construction of pyrimidine derivatives under mild conditions. Subsequent bromination and hydroxylation steps are then employed to introduce the desired substituents at positions 6 and 4, respectively. The optimization of these steps has been a focus of recent research efforts to enhance yield and purity.

In terms of physical properties, (6-Bromopyrimidin-4-yl)methanol is known to be a crystalline solid with a melting point of approximately 130°C. Its solubility in common organic solvents such as dichloromethane and ethanol has been determined, making it suitable for various analytical techniques including high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy.

The biological evaluation of (6-Bromopyrimidin-4-yl)methanol has revealed its potential as an anti-inflammatory agent. Studies conducted by researchers at the University of California have shown that this compound can effectively inhibit cyclooxygenase (COX) enzymes, which are key players in inflammation and pain signaling. These findings suggest that (6-Bromopyrimidin-4-yl)methanol could serve as a lead compound for the development of novel anti-inflammatory drugs.

Furthermore, computational studies using molecular docking techniques have provided insights into the binding modes of (6-Bromopyrimidin-4-yl)methanol with various protein targets. These studies have highlighted the importance of the bromine substituent in stabilizing interactions within the binding pocket, thereby enhancing the compound's bioactivity.

In conclusion, (6-Bromopyrimidin-4-yl)methanol, with its unique structure and promising biological properties, represents a valuable addition to the arsenal of compounds being explored for therapeutic applications. As research continues to uncover its full potential, this compound is expected to play a significant role in advancing drug discovery efforts in oncology and inflammation management.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)